Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Neurotrope Inc. (NTRP)

1.16   -0.02 (-1.69%) 02-14 16:00
Open: 1.17 Pre. Close: 1.18
High: 1.18 Low: 1.14
Volume: 184,371 Market Cap: 15M
Neurotrope Inc is biopharmaceutical company with product candidates in pre-clinical and clinical development. It is engaged in developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.181 - 1.191 1.191 - 1.197
Low: 1.12 - 1.131 1.131 - 1.138
Close: 1.146 - 1.163 1.163 - 1.174

Technical analysis

as of: 2020-02-14 4:31:12 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 3.25     One year: 4.50
Support: Support1: 1.05    Support2: 0.87
Resistance: Resistance1: 2.78    Resistance2: 3.85
Pivot: 1.19
Moving Average: MA(5): 1.18     MA(20): 1.23
MA(100): 0.91     MA(250): 3.72
MACD: MACD(12,26): 0.02     Signal(9): 0.03
Stochastic oscillator: %K(14,3): 38.34     %D(3): 26.27
RSI: RSI(14): 49.35
52-week: High: 8.40  Low: 0.63  Change(%): -73.1
Average Vol(K): 3-Month: 116789  10-Days: 27925

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
NTRP has closed above bottom band by 33.8%. Bollinger Bands are 63% narrower than normal. The narrow width of the bands suggests low volatility as compared to NTRP's normal range. The bands have been in this narrow range for 96 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2020-01-22
Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding
Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP ) gap-opened sharply higher on above 50 times average volume following a corporate update from the company. Detailed Analysis Shows Promise Following the completion of data analysis for a confirmatory Phase 2 study dubbed "203 study" that evaluated its experimental Alzheimer's disease candidate Bryostatin-1 , Neurotrope said the data showed improvement in cognitive function of pre-specified Moderate Stratum patients at week 13, which is the primary endpoint. "The data suggests that Bryostatin may still be considered a new approach to Alzheimer's treatment," said Dr. Marwan Sabbagh, who helped design the trial … Full story available on Benzinga.com

2019-09-10
The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) ( reacted to positive Nuplazid data) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Scpharmaceuticals Inc (NASDAQ: SCPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Pfenex Inc (NYSE: PFNX ) Down In The Dumps (Biotech stocks that hit 52-week lows on Sept. 9.) Advaxis, Inc. (NASDAQ: ADXS ) (reacted to third-quarter results) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Endologix, Inc. (NASDAQ: ELGX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Illumina, Inc. (NASDAQ: ILMN ) Neurotrope Inc (NASDAQ: NTRP ) ( Alzheimer's disease drug did not meet the primary endpoint) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Retrophin Inc (NASDAQ: RTRX ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Trinity Biotech plc (NASDAQ: TRIB ) Transenterix Inc (NYSE: TRXC ) See also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Translate Bio Discontinues Development Of mRNA Therapy Translate Bio Inc (NASDAQ: TBIO ) said in a clinical pipeline update that it has decided to discontinue the development of MRT5201, a liver-targeted treatment for ornithine transcarbamylase, or OTC, deficiency.

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 13.07
Shares Float (M) 9.83
% Held by Insiders 25.28
% Held by Institutions 12.16
Shares Short (K) 675
Shares Short P. Month (K)

Stock Financials

EPS -1.373
Book Value (p.s.) 1.460
PEG Ratio
Profit Margin
Operating Margin
Return on Assets (ttm) -67.2
Return on Equity (ttm) -114.5
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -1.270
Qtrly Earnings Growth
Operating Cash Flow (M) -11.69
Levered Free Cash Flow (M) -5.81

Stock Valuations

P/E -0.84
P/E Growth Ratio -0.02
P/BV 0.79
P/S
P/CF -1.30

Dividends & Splits

Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2017-01-11
Last Split Ratio 0.031
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.